[17], as approved by our institutional ethics committee, to avoid chemical interference with the analysis of testicular tissue, sperm parameters, and antioxidant biomarkers
Jastreboff et al., 2023 en obesidad sin diabetes)
Tirzepatide initiates appetite suppression within 2472 hours of your first injection as GLP-1 and GIP receptors engage in the hypothalamus and brainstem
doi: 10.1016/j.biocel.2016.07.017 41
This piece is an attempt to fill that gap, sourced from peer-reviewed literature rather than marketing copy
The trial program has evolved from glycemic-safety and outcomes studies in T2D (the LEADER, SUSTAIN-6, REWIND, EXSCEL, and PIONEER 6 era [10][13], [19]), to outcomes trials in expanded populations including obesity without diabetes (SELECT [3]), HFpEF with obesity (SUMMIT [5], with a companion semaglutide program in STEP-HFpEF [20], [21]), CKD (FLOW [22]), and an active-comparator setting (SURPASS-CVOT [6])